Compare · SLP vs VRSN
SLP vs VRSN
Side-by-side comparison of Simulations Plus Inc. (SLP) and VeriSign Inc. (VRSN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both SLP and VRSN operate in EDP Services (Technology), so they compete in similar markets.
- VRSN is the larger of the two at $26.84B, about 83.6x SLP ($320.9M).
- Over the past year, SLP is down 41.7% and VRSN is up 4.1% - VRSN leads by 45.8 points.
- VRSN has been more active in the news (9 items in the past 4 weeks vs 3 for SLP).
- SLP has more recent analyst coverage (10 ratings vs 6 for VRSN).
- Company
- Simulations Plus Inc.
- VeriSign Inc.
- Price
- $15.98+0.76%
- $291.49-1.15%
- Market cap
- $320.9M
- $26.84B
- 1M return
- -0.59%
- +4.60%
- 1Y return
- -41.68%
- +4.14%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1998
- News (4w)
- 3
- 9
- Recent ratings
- 10
- 6
Simulations Plus Inc.
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments. It also provides PKPlus, a program that provides the functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to satisfy regulatory agency requirements for noncompartmental analysis and compartmental PK modelling; ADMET Predictor, a chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, a molecule drawing program or sketcher. In addition, it offers KIWI, a cloud-based web application to organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program; DILIsym, a quantitative systems pharmacology software; NAFLDsym, a simulation program for analyzing nonalcoholic fatty liver disease; RENAsym for investigating and predicting drug-induced or acute kidney injury; IPFsym, a software tool to treat or cure idiopathic pulmonary fibrosis; and the Monolix Suite, a solution for modeling and simulation. Further, the company provides population modeling and simulation contract research services; and clinical-pharmacology-based consulting services in support of regulatory submissions. It serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. The company was founded in 1996 and is headquartered in Lancaster, California.
VeriSign Inc.
VeriSign, Inc., together with its subsidiaries, provides domain name registry services and internet infrastructure that enables internet navigation for various recognized domain names worldwide. It enables the security, stability, and resiliency of internet infrastructure and services, including providing root zone maintainer services, operating two of the 13 internet root servers; and offering registration services and authoritative resolution for the .com and .net domains, which support global e-commerce. VeriSign, Inc. was incorporated in 1995 and is headquartered in Reston, Virginia.
Latest SLP
- Chief Revenue Officer Dibella John Anthony Ii sold $16,500 worth of shares (1,000 units at $16.50) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 87,140 units (SEC Form 4)
- Director Woltosz Walter S sold $261,450 worth of shares (15,000 units at $17.43) as part of a pre-agreed trading plan, decreasing direct ownership by 0.46% to 3,252,800 units (SEC Form 4)
- Simulations Plus to Participate in the 23rd Annual Craig-Hallum Institutional Investor Conference
- President, Services Solutions Fiedler-Kelly Jill exercised 1,000 shares at a strike of $10.05 and sold $16,530 worth of shares (1,000 units at $16.53) as part of a pre-agreed trading plan (SEC Form 4)
- Simulations Plus and NVIDIA Collaborate to Scale GPU-Accelerated, AI-Assisted Modeling Workflows
- Chief Revenue Officer Dibella John Anthony Ii sold $14,980 worth of shares (1,000 units at $14.98) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 88,140 units (SEC Form 4)
- Director Woltosz Walter S sold $226,950 worth of shares (15,000 units at $15.13) as part of a pre-agreed trading plan, decreasing direct ownership by 0.46% to 3,267,800 units (SEC Form 4)
- Director Evans Sharlene was granted 2,117 shares, increasing direct ownership by 14% to 17,173 units (SEC Form 4)
- Director Woltosz Walter S was granted 2,117 shares, increasing direct ownership by 0.06% to 3,282,800 units (SEC Form 4)
- Director Weiner Daniel L was granted 2,117 shares, increasing direct ownership by 15% to 16,547 units (SEC Form 4)
Latest VRSN
- Exec. Chairman, Pres, & CEO Bidzos D James sold $981,646 worth of shares (3,300 units at $297.47), decreasing direct ownership by 0.75% to 439,339 units (SEC Form 4)
- EVP, Gen Counsel & Secretary Indelicarto Thomas C sold $146,725 worth of shares (500 units at $293.45), decreasing direct ownership by 1% to 37,051 units (SEC Form 4)
- Director Armstrong Courtney D bought $4,929 worth of shares (16 units at $305.81), increasing direct ownership by 0.26% to 885 units (SEC Form 4)
- Counterfeiters Stole an Estimated $500K From One Brand -- Now This NASDAQ Apparel Stock Is Building the AI That Fights Back
- VeriSign Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- EVP, Chief Financial Officer Calys John covered exercise/tax liability with 179 shares, decreasing direct ownership by 0.56% to 31,842 units (SEC Form 4)
- EVP, Gen Counsel & Secretary Indelicarto Thomas C covered exercise/tax liability with 706 shares, decreasing direct ownership by 2% to 37,496 units (SEC Form 4)
- EVP - Technology & CSO Mcpherson Danny R covered exercise/tax liability with 726 shares, decreasing direct ownership by 2% to 34,470 units (SEC Form 4)
- Exec. Chairman, Pres, & CEO Bidzos D James covered exercise/tax liability with 1,646 shares, decreasing direct ownership by 0.37% to 442,490 units (SEC Form 4)
- EVP - Technology & CSO Mcpherson Danny R sold $1,355,106 worth of shares (5,000 units at $271.02), decreasing direct ownership by 12% to 35,195 units (SEC Form 4)